Pierre Gholam, MD, presents the case of a 61-year-old woman with hepatocellular carcinoma (HCC).
A 61-Year-Old Woman With Hepatocellular Carcinoma
Dr Gholam, MD, provides expert analysis on the prognosis and treatment of a patient with unresectable HCC.
An expert in the treatment of HCC comments on first-line therapeutic options for patients with previously untreated, advanced HCC.
Dr Gholam reviews the study design and key data from the phase 3 REFLECT trial.
Gastroenterology expert, Dr Pierre Gholam, discusses the efficacy and safety data from the phase 3 IMbrave150 trial.
Pierre Gholam, MD, discusses future directions and novel therapeutic agents for the treatment of unresectable HCC.
A key opinion leader shares clinical practice pearls for the treatment of patients with unresectable HCC.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
